Compare ARK Innovation ETF (ARKK) vs Axogen Inc (AXGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Innovation ETF vs Axogen Inc — how do they compare? ARK Innovation ETF trades at $79.8, while Axogen Inc trades at $40.21 (market cap $2.16B). The key difference: Axogen Inc is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKK | AXGN | |
|---|---|---|
52-Week High | $92.50 | $46.19 |
52-Week Low | $63.52 | $11.28 |
Market Cap | — | $2.16B |
Sector | — | Technology |
Enterprise Value | — | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $80.25, down 1.58% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF has gained about 2% year-to-date through late June, sitting near its pivot point of $81. Recent news highlights Cathie Wood's continued stock purchases during pullbacks while the fund faces criticism for its 0.75% expense ratio and underperformance relative to broader tech markets.
The outlook remains mixed with strong technical momentum but fundamental concerns about fees and concentrated exposure to volatile innovation stocks. Key risks include Tesla's 10% weighting creating single-stock vulnerability and the fund's history of 37.88% losses over five years despite recent investor interest resurgence.
AXGN trades at $40.58, down 6.97% today, with neutral technical signals and mixed earnings performance. The company maintains strong gross margins of 75.01% but reported a net loss of $15.70 million in 2025. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $47.60 consensus price target, representing 17% upside potential from current levels.
While AXGN shows promising revenue growth and institutional support, persistent net losses and recent earnings misses create execution risk. The stock's valuation appears stretched with a P/S ratio of 8.12 despite negative profitability metrics. Positive reimbursement developments and nerve repair market expansion provide growth catalysts if the company can achieve sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
